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Summary Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy
(minimum follow up 21 months) were randomised to receive either adriamycin 70 mgm 2 i.v. 3-weekly for 8
cycles (Regimen A) or adriamycin 35 mgm-2 i.v. 3-weekly for 16 courses (Regimen B). Objective responses
were seen in 14/24 (58%) patients with regimen A (4 complete) and 6/24 (25%) with regimen B (1 complete)
(P<0.02). The median duration of response was 14 months with regimen A and 6.5 months with regimen B.
The median duration of survival was 20 months and 8 months respectively (P<0.01). The toxicity was similar
with each regimen. There was no evidence of deterioration in left ventricular ejection fraction nor congestive
heart failure in any patient. It is concluded that when given at 3-weekly intervals adriamycin is a more
effective treatment for advanced breast cancer at higher rather than lower dosage.
Adriamycin is the most active agent currently available for
the treatment of disseminated breast carcinoma. The
addition of other cytotoxic drugs to it in combinations has
not led to higher response frequencies (Steiner et al., 1983;
Amiel et al., 1985; Chlebowsky et al., 1983). Evidence from
experimental tumours indicates that, within limits, the
response rate to chemotherapy is proportional to the
concentration of cytotoxic drug present (Frei et al., 1980).
The optimal dose schedule in which to administer
adriamycin as single agent has been unclear. High doses are
associated with severe side effects and so it is important to
determine whether or not such doses achieve better
therapeutic results than lower doses given at similar
intervals.
In one study of 171 patients with advanced breast
carcinoma, 103 deemed 'good-risk' were randomised to
receive adriamycin in doses of 75mgm 2, 60mgm 2 or
45mgm-2 and the response frequencies were not
significantly different at 25%, 37% and 32% respectively,
nor were there significant differences for response duration
(O'Bryan et al., 1977). In another trial, the overall response
rate achieved in 53 evaluable patients treated with
adriamycin as primary chemotherapy for disseminated breast
carcinoma was 57% (Steiner et al., 1983). In this trial
adriamycin was given at a dose of 70mgm-2 i.v. at 3-weekly
intervals. In a further trial using lower doses of adriamycin,
albeit as secondary chemotherapy, the response rate was
only 27% (Creech et al., 1980). A low dose of adriamycin
could have the potential advantage that the duration of drug
administration could be extended before the safe maximum
cumulative dose had been reached.
Prospective, randomised, controlled clinical trials using
different doses of cytotoxic agents are required to determine
if clinically important dose response effects exist. The present
trial compares two different dose levels of adriamycin in
patients with disseminated breast carcinoma who have not
undergone previous cytotoxic chemotherapy.
Patients and methods
Forty-eight patients with progressive histologically proven
disseminated breast carcinoma previously untreated with
cytotoxic chemotherapy, but resistant to conventional
endocrine therapy, were randomly allocated to receive either
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regimen A, adriamycin at high dose, or regimen B,
adriamycin at low dose (see below). The patients were
entered at the Instituto Portugues de Oncologia Francisco
Gentil, Lisboa, from 1st January 1984 to 31st January 1985
with last follow up 31st October 1986. Eligibility criteria
included measurable and/or evaluable disease, no previous
chemotherapy (adjuvant or for advanced disease), age<65
years, a UICC performance status <2, adequate hepatic
and renal function, a minimum white blood cell count
.4000pl-1, a platelet count of _100,000pl-1 and at least
an interval of 4 weeks after stopping additive or performing
ablative endocrine therapy. Patients with brain metastases or
osteoblastic bone lesions and pleural effusions as the sole
manifestation of advanced disease were not eligible.
Before each course of chemotherapy, a full physical
examination was carried out. All palpable or superficial
lesions were measured in two perpendicular diameters and
visible lesions photographed. Base line studies included
hepatic ultrasonogram, a chest radiograph, an isotopic bone
scan with radiographs of areas of increased uptake and
haematological and biochemical screens. Relevant
radiographs were repeated at 2 monthly intervals and the
isotopic bone and liver scan at 3 monthly intervals if the
baseline studies were abnormal. In all the patients,
radionuclide angiocardiography and electrocardiograms were
performed before starting chemotherapy and after every
third cycle of treatment. The ejection fraction was calculated
from the volume change in the left ventricle using standard
methods and the images were reviewed simultaneously on a
VDU monitor in 'cine' mode.
Before starting chemotherapy, the patients were stratified
according to age and then randomly allocated to one of the
two treatment groups (regimen A or B):
Patients less than 60 years old:
Regimen A - Adriamycin 70mg/M-2 i.v. (max 120mg) every
3 weeks for 8 courses:
Regimen B- Adriamycin 35mgm-2 i.v. (max60mg) every 3
weeks for 16 cycles.
After the above or earlier ifprogression ofdisease occurred,
treatment was continued as follows: cyclophosphamide
100mgm-2 p.o. (max 150mg) days 1-14, methotrexate
30mgm-2 i.v. (max 50mg) days 1 and 8, 5-fluorouracil
600mgm-2 i.v. (max 1000mg) days 1 and 8, repeating
cycles every 4 weeks (CMF).
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Patients 60 years old or more:
Regimen A - Adriamycin 60mgm-2 i.v. (max 100mg) every
3 weeks for 8 courses;
Regimen B - Adriamycin 30mgm-2 i.v. (max 50mg) every 3
weeks, for 16 cycles.
After the above or earlier if progression of disease
occurred, the following CMF schedule was used: cyclo-
phosphamide 100mgm-2 p.o. (max 150mg) days 1-14,
methotrexate 20m m- 2 i.V. (max 40mg) days 1 and 8, and
5-fluorouracil 400mgm-2 (max 1,000mg) days I and 8,
repeating cycles every 4 weeks.
The following dose modifications were adopted in the
presence of myelosuppression. With a white blood count
between 2,000 and 3,999 cells l-1 and a platelet count
between 90,000 and 99,999pl- 1, the dose of adriamycin was
delayed for 1 week only when recovery of the leukocyte
count to >4,000 1-1 and a platelet count to > 100,000pl-1
allowed full dosage to be given. With a white blood count
below 2,000 cells,ul -1 and a platelet count <90,000,
treatment was stopped until the level of leukocytes reached
>4,000jul 1 and platelets . 100,000pjil.
The courses of cytotoxic chemotherapy were usually
administered on an out-patient basis and at least 2 cycles of
treatment were given before a regimen was considered
ineffective.
Both treatment schedules were evaluated for response rate
(Hayward et al., 1977), median duration of response, median
survival time and toxicity. The duration of response was
from the beginning of chemotherapy until disease
progression. Survival was calculated from the date of first
cycle of therapy to death or censored at date of last follow
up (31st October 1986) for patients still alive and was
analysed by the life table method. The significance of
differences between responses was determined by the chi-
square test and the log rank method was used to study
differences for duration of response to treatment and
survival. In this trial the records of all patients were
externally reviewed to verify the response categories without
knowledge of the Adriamycin dosage.
Results
Twenty-four patients were randomised to receive regimen A
and 24 to regimen B. Two patients in the high dose groups
and three in the low dose received the treatment schedule for
patients .60 years old. The characteristics of the patients in
each group are shown in Table I. The groups are
comparable for median age at diagnosis, median time from
diagnosis to start chemotherapy, previous treatments, initial
axillary involvement, median performance status, post-
operative disease free-interval, menopausal status and
predominant sites involved.
Antitumour effects
The results of treatment are shown in Table II. With
regimen A, 14/24 patients (58%) achieved an objective
regression, 4 being complete (17%), compared to 6/24
patients (25%) with regimen B, 1 of them attaining complete
remission (4%). The difference between these response rates
was significant (X2 =5.49; P<0.02).
The median duration of remission was 14 months (range
4-29) for regimen for regimen A and 6.5 months (range 4-14)
for regimen B (X2 =5.68; P<0.01). The survival life table
curve is shown in Figure 1. The median probability of
survival was 20 months for regimen A and 8 months for
regimen B (X2 = 7.93; P<0.005).
At last follow-up (31st October 1986), 10 patients were
still alive in the high dose group (regimen A), one of them in
Table I Characteristics of patients
Regimen A Regimen B
(n=24) (n=24)
Median age at diagnosis (yrs) 45 47
(range 30-65) (range 30-65)
Median time from diagnosis 25 27
to chemotherapy (months) (range 1-117) (range 1-113)
Previous treatments:
Mastectomy +radiotherapy 11 12
(stage I and II)
Axillary involvement:
Positive 8 9
Negative 3 3
Primary radiotherapy
+mastectomy (stage III) 13 12
Oophorectomy 5 6
Androgens and/or antioestrogens 14 15
Post-operative disease free interval
(for stage I and II)
None 2 1
<2 years 5 5
.2 years 4 6
Dominant sites involved
Soft tissue 11 11
Osseous 3 4
Lung/pleura 8 7
Hepatic 2 2
Table II Objective responses
Number ofpatients
Regimen A Regimen B
(n=24) (n=24) P
Objective regressions
Complete response 4 (17%) 58% 1 (4%) 25% 0.02
Partial response 10 (42%) 5 (21%)j
Duration of response
Median (months) 14 6.5 0.01
Range 4-28 4-14
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Figure 1 Survival of patients with advanced breast cancer.
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complete remission, while in the low dose group (regimen B),
3 patients were alive with no one in remission.
The 14 responding patients on regimen A received the full
eight courses of adriamycin before changing to CMF. On
regimen B, the responding patients received at least 8 courses
of therapy, but only two received 16 cycles of treatment
before starting CMF. The cumulative doses of adriamycin
administered in regimen A ranged from 330mg to 960mg
and, in regimen B, between 150mg and 960mg. The median
and the mean doses of adriamycin given on regimen A were
720mg and 637mg respectively, but only 255mg and 250mg
for regimen B.
In the 14 objective responders in the high dose group,
there were only 4 patients with a previous response to
endocrine treatment. In the low dose group, only two of the
6 responders had responded to prior hormone therapy.
After CMF was started, 2 patients, both in the high dose
group, achieved an improved response category, complete in
one instance.
Toxicity
The toxic manifestations are listed in Table III. The
tolerance to cytotoxic chemotherapy was generally
acceptable and overlapping in both groups of patients for
nausea, vomiting, alopecia and myelosuppression. There
were no cases of thrombocytopenia in either arm of the trial.
In 18 patients on regimen A and 19 on regimen B, a delay of
one week in the administration of adriamycin was necessary
on one or more occasions. In three patients on regimen A
Table III Toxicity
Number ofpatients
Regimen A Regimen B
(n =24) (n =24)
Haematological toxicity
Leukocyte nadir (pl -1)a
>4,000 5 6
2,000-3,999 15 16
1,000-1,999 4 2
Platelet nadir (,Il- I)a
<100.000 0 0
Nausea and vomitingb 24 24
Alopecia 24 22
Cardiotoxicity 0 0
Septicaemiac 1 0
aAtday 21 ofcourse;bWHO grade 2or 3;grade4notobserved;
and coccurred during subsequent CMF.
and two in regimen B, a white blood cell count of
<2,000p1-' necessitated a delay in treatment of two weeks
before treatment could be resumed. In one patient on
regimen A there was prolonged leucopenia and chemo-
therapy had to be discontinued. There was no deterioration
in left ventricular ejection fraction assessed by isotopic gated
angiocardiography nor congestive heart failure in any of the
patients studied. One case of septicaemia occurred and was
treated successfully with antibiotics, but this was while on
treatment with CMF. No drug related deaths occurred. The
median survival of non-responders on each regimen was
similar (regimen A - 10 months, regimen B - 8 months)
indicating that there was no additional toxicity of high dose
treatment in non-responders.
Discussion
The results of this prospective, randomised trial show a
significantly better therapeutic effect for a high dose of
adriamycin (70mgm-2 i.v. 3-weekly) compared to a low
dose regimen (35mgm-2) in patients with disseminated
breast carcinoma. The response rates were 58% and 25%
respectively and the median survival was 20 months for the
high dose and 8 months for the low dose group. Because of
the marked and significant difference in overall response rate
between the two regimens after the accrual of 48 patients, it
was deemed unethical to continue further entry to the trial.
The response rate of 58% with the high dose schedule of
adriamycin 70mgm-2 i.v. 3-weekly for 8 cycles is identical
to previous experience with adriamycin either alone or in
combination (Steiner et al., 1983; Amiel et al., 1985). No
potential clinical advantage was demonstrated for using a
low dose of adriamycin to enable the duration of drug
administration to be doubled. The results here confirm
previous findings indicating that an objective response to
previous endocrine treatment does not predict response to
subsequent cytotoxic chemotherapy (Creech et al., 1980).
The administration of adriamycin in either regimen was not
associated with cardiotoxicity. For both regimens, there was
an acceptable tolerance compatible with out-patient care.
In conclusion, the present prospective randomised clinical
trial demonstrates that used at 3-weekly intervals there is a
significant advantage for higher rather than lower doses of
adriamycin in the treatment of patients with disseminated
breast carcinoma. It is possible that lower doses given at
more frequent intervals could give results equivalent to high
dose treatment, but probably at greater inconvenience to the
patient. Because treatment for advanced breast cancer is
given to relieve symptomatic disease and because palliation
results from achieving objective responses, the result of this
trial is of some importance for guiding the optimal selection
of treatment for this disease.
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